Do you disagree that there are approximately 50,000 patients on TKI'S annually? And if you agree, what % of that market do you think Pona will capture?
Peter stated that "about 1/3 of patients fail Gleevac", I took that to mean that 1/3 of all patients fail and I may have over estimated that fact. What % of the patients do you believe fail annually, either by intolerance or a mutation?
What do you believe to be the dollar value of Pona's initial penetration into the market?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.